ALLMedicine™ Paronychia Center
Research & Reviews 290 results
https://www.mdedge.com/hematology-oncology/article/261095/melanoma/spectrum-dermatologic-adverse-events-associated
Walter Alexander
Feb 7th, 2023 - A case series of epidermal growth factor receptor (EGFR) exon 20 insertion–mutated advanced non–small cell lung cancer patients with dermatologic adverse events (dAEs) subsequent to treatment with amivantamab showed classic toxic effects associate.
https://doi.org/10.1097/CAD.0000000000001443
Anti-cancer Drugs; Tan X, Chen S et. al.
Feb 3rd, 2023 - Osimertinib is recommended as the first-line treatment of advanced non-small cell lung cancer (NSCLC) in adults. The most commonly reported adverse events for osimertinib are skin effects, diarrhea, nausea, decreased appetite, fatigue, paronychia,...
https://doi.org/10.1007/s10637-023-01328-9
Investigational New Drugs; Ishikawa E, Yokoyama Y et. al.
Jan 14th, 2023 - Potential novel strategies for adverse event (AE) management of osimertinib therapy, including therapeutic drug monitoring and the use of biomarkers, have not yet been fully investigated. This study aimed to evaluate (1) the relationship between e...
https://doi.org/10.1111/ijd.16564
International Journal of Dermatology; Rocha BP, Verardino G et. al.
Jan 12th, 2023 - Chronic paronychia is an inflammatory process of the nail folds lasting more than 6 weeks. Clinically, there is hypertrophy and retraction of the folds and absence of the cuticle. Treatment involves clinical measures and, when there is no response...
https://doi.org/10.1186/s12916-022-02669-7
BMC Medicine; Wang X, Luo Z et. al.
Jan 5th, 2023 - HL-085 is a selective, orally administered MEK1/2 inhibitor. We aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations. This was a multicenter phase 1 study. HL-085 was administered twice da...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532717
Drugs Califano R, Tariq N et. al.
Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...
Drugs 3 results see all →
Clinicaltrials.gov 12 results
https://clinicaltrials.gov/ct2/show/NCT03908892
Aug 15th, 2022 - This is a randomized control trial evaluating the efficacy of zanthoxylum nitidum tincture on preventing progression of paronychia caused by afatinib from grade 1 to grade 2/3. Enrolled participates will randomly receive original treatment or orig...
https://clinicaltrials.gov/ct2/show/NCT05165082
Jun 8th, 2022 - Background: EGFR inhibitors (EGFRi) have been used to treat a wide variety of cancers nowadays. One of the major side effects of EGFRi is paronychia, which was not fatal but may caused huge negative impact on patient's daily activities. Current gu...
https://clinicaltrials.gov/ct2/show/NCT03167268
Sep 9th, 2021 - Background and rationale: EGFR represents the main and more studied signal activation pathway in the development of colorectal carcinoma. KRAS, NRAS, BRAF and PI3KA mutations and ERBB2 and MET amplification are responsible for most of the cases of...
https://clinicaltrials.gov/ct2/show/NCT04087629
Aug 9th, 2021 - Topical steroids are the mainstays of treatment for many cutaneous reactions and disorders. Steroids are known to cause many side effects and few effective pharmacologic alternatives exist. Contact dermatitis is observed in 56% of patients with cu...
https://clinicaltrials.gov/ct2/show/NCT03421912
Jul 9th, 2021 - The arrival of new therapeutic strategies such as targeted therapies has led to real progress in the treatment of cancers. Tyrosine kinase inhibitors and antibodies to epidermal growth factor receptors (EGFR), or iEGFR, target one of the major pat...
News 154 results
https://www.mdedge.com/hematology-oncology/article/261095/melanoma/spectrum-dermatologic-adverse-events-associated
Walter Alexander
Feb 7th, 2023 - A case series of epidermal growth factor receptor (EGFR) exon 20 insertion–mutated advanced non–small cell lung cancer patients with dermatologic adverse events (dAEs) subsequent to treatment with amivantamab showed classic toxic effects associate.
https://www.mdedge.com/dermatology/article/260431/contact-dermatitis/botanical-briefs-daffodils-narcissus-species
Kevin P. Lee, MD, Dirk M. Elston, MD
Dec 30th, 2022 - Contact dermatitis is a common problem in the floral bulb industry and is considered an occupational disease. Daffodils (Narcissus species)(Figure) are thought to be the most common cause of irritant contact dermatitis among florists.
https://www.mdedge.com/dermatology/article/260428/nonmelanoma-skin-cancer/epidermal-growth-factor-receptor-inhibitor
William Lewis, MD, Amy Forrestel, MD et. al.
Dec 30th, 2022 - Epidermal growth factor receptor (EGFR) inhibitors cause numerous cutaneous adverse events (AEs), including papulopustular eruptions, paronychia, acral fissures, xerosis, alopecia, and trichomegaly. 1 Symmetrical drug-related intertriginous and fle.
https://www.onclive.com/view/dr-piotrowska-on-the-management-of-paronychia-associated-with-egfr-tkis
Nov 17th, 2022 - Zofia Piotrowska, MD, assistant professor of medicine, Harvard Medical School, assistant in medicine, Massachusetts General Hospital, discusses the management of paronychia associated with EGFR TKIs. Although paronychia is an adverse effect (AE) ...
https://www.onclive.com/view/sunvozertinib-showcases-early-safety-efficacy-in-egfr-exon-20-mutated-nsclc
Oct 30th, 2022 - Sunvozertinib (DZD9008) elicited promising responses as a second- or later-line treatment in patients with non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to D. Ross Camidge, MD, PhD, who added that further...